Comparative Pharmacology
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus POLOCAINE W LEVONORDEFRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus POLOCAINE W LEVONORDEFRIN.
DECADRON W/ XYLOCAINE vs POLOCAINE W/ LEVONORDEFRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
Polocaine (mepivacaine) is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, inhibiting the initiation and conduction of nerve impulses. Levonordefrin is a vasoconstrictor that acts as an alpha-adrenergic agonist, causing local vasoconstriction to reduce systemic absorption of mepivacaine and prolong duration of action.
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
Dental local anesthesia: 1:100,000 epinephrine equivalent. For Polocaine (mepivacaine) 2% with levonordefrin 1:20,000, typical adult dose: 1-3 mL infiltrations or 2-4 mL nerve blocks; maximum 6.8 mg/kg (mepivacaine) or about 5.8 mL of 2% solution for a 70 kg adult. Maximum per session: 20 mL of 2% mepivacaine.
None Documented
None Documented
Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease).
Terminal elimination half-life of prilocaine is approximately 1.5 hours (range 1-2 hours); clinically, this correlates with duration of anesthesia for infiltration and nerve block procedures.
Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged).
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination; <2% excreted unchanged in urine; major metabolites are glucuronide and sulfate conjugates excreted renally; biliary excretion is minor.
Category C
Category C
Corticosteroid/Local Anesthetic Combination
Local Anesthetic Combination